article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

As biomarkers become increasingly relevant in indicating the workings and effects of novel therapies, their potential as valuable clinical and regulatory endpoints is also gaining recognition. Biomarkers can play a crucial role throughout clinical development, especially in early phases. Bagyinszky E, et al. 21(10):3517.

article thumbnail

Coordinating the Cell Journey: Essentials in Early Clinical Development

PPD

The role of the clinical logistics monitor (CLM) is a focal point of contact and an escalation point to the internal and external teams. Explore our early development services LEARN MORE The post Coordinating the Cell Journey: Essentials in Early Clinical Development appeared first on PPD Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How the FSP Model Augments Biotech Sponsors’ Internal Capabilities

PPD

Meeting the never-ending challenges of drug development in this active environment — including pressure to identify drug prospects earlier and hire more conservatively — frequently leads biotech companies to outsource some portion of clinical development functions.

article thumbnail

ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference

The Pharma Data

Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer’s disease clinical development portfolio at the Alzheimer’s Association International Conference (AAIC), which will be held in Denver, Colorado and online July 26-30, 2021. Biogen Inc.

article thumbnail

Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer

The Pharma Data

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. . ” About Ascletis.

article thumbnail

New cell therapy model accelerates cancer treatment development

Drug Target Review

My focus has always been on advancing novel medicines from research to clinical development. We believed the missing piece was essentially an internal biotech at MD Anderson – one that could collaborate with researchers to industrialise their processes for cell therapies.

article thumbnail

FSP Engagements Continue to Gain Popularity, Drive Success

PPD

A large majority of drug developers utilize FSP or hybrid FSP/FSO models, half are “heavy users” Heavy users: Those that use FSP or hybrid FSP/FSO models for most of their clinical development outsourcing. Heavy users leverage these models for nearly three-quarters of their outsourcing.